糖尿病性视网膜病变抗血管内皮生长因子治疗进展

Update on anti-vascular endothelial growth factor therapy for diabetic retinopathy

血管内皮生长因子(VEGF)在糖尿病性视网膜病变(DR)发病过程中的重要作用逐渐得到广泛而深入的认识。阻断VEGF信号转导通路上的任何环节即可抑制VEGF发挥其生物学特性,从而达到治疗目的。文章以治疗DR的抗VEGF药物的不同作用位点为分类依据,对目前处于临床或实验室研究阶段的各类药物的机制和疗效等进行综述。

A comprehensive consensus has been reached that vascular endothelial growth factor（VEGF） plays an important role in the pathogenesis of diabetic retinopathy（DR）.Theoretically,a block to any step of the VEGF signal pathway may interrupt the biological function of VEGF,so that the therapeutic effect can be achieved.This paper reviews the mechanisms and efficacies of different anti-VEGF drugs,either in clinical trial or laboratory research phase,that have been used in the treatment of DR.